Can a stronger rituximab dose prevent relapse in kids with ITP?
NCT ID NCT04323748
First seen Apr 25, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study tests a stronger, more frequent dose of the drug rituximab in children and young adults (ages 1-21) with newly diagnosed immune thrombocytopenic purpura (ITP) who are at high risk for complications. The goal is to see if this approach can improve platelet counts and reduce the chance of the disease coming back. The study will also monitor for side effects and measure quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
New York Medical College
RECRUITINGVahalla, New York, 10595, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.